Recap: Eagle Pharmaceuticals First Quarter Results

Actions of Eagle Pharmaceuticals (NASDAQ: EGRX) was unchanged after the company’s first quarter earnings release.

Quarterly results

Earnings per share fell 71.43% year-over-year to $ 0.24, which missed the estimate of $ 0.65.

Revenue of $ 41,249,000 was down 10.37% from the same period last year, which missed the estimate of $ 45,410,000.

Advice

Eagle Pharmaceuticals has not released a revenue forecast at this time.

The revenue forecast has not been released by the company at this time.

Call details

Date: May 10, 2021

Time: 8:30 a.m.

ET webcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=https%3A%2F%2Finvestor.eagleus.com%2F&eventid=3082041&sessionid=1&key=83C4DAA2D59D2French®ource&sessionid=1&key=83C4DAA2F59D2Frame®58page02

Price action

Company high in 52 weeks was $ 56.16

Company low in 52 weeks was $ 36.48

Price action in the last quarter: + 3.30%

Company Profile

Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and markets injectable products in the fields of intensive care, orphan diseases and oncology. Its product portfolio includes four approved products: Argatroban, Ryanodex, Belrapzo and Bendeka. The company currently has several product candidates in advanced stages of development and under review for approval by the Food and Drug Administration.


Source link

About Catherine Sherrill

Check Also

Why NRx Pharmaceuticals’ stock is plummeting today

What happened Actions of NRx Pharmaceuticals (NASDAQ: NRXP) were trading down 7.2% at 11:25 am …

Leave a Reply

Your email address will not be published. Required fields are marked *